Skip to main content

CORRECTION article

Front. Oncol., 14 January 2022
Sec. Gynecological Oncology
Volume 11 - 2021 | https://doi.org/10.3389/fonc.2021.840551
This article is part of the Research Topic Familial Cancer in China: From Detection to Screening and Management View all 7 articles

Corrigendum: Identification of BRCA1:c.5470_5477del as a Founder Mutation in Chinese Ovarian Cancer Patients

This article is a correction to:

  1. Identification of BRCA1:c.5470_5477del as a Founder Mutation in Chinese Ovarian Cancer Patients

    1. Read original article
Jun Li,&#x;Jun Li1,2†Sile Han&#x;Sile Han1†Cuiyun Zhang,Cuiyun Zhang1,2Yanlin LuoYanlin Luo3Li WangLi Wang3Ping WangPing Wang4Yi WangYi Wang5Qingxin XiaQingxin Xia5Xiaoyan Wang,Xiaoyan Wang1,2Bing Wei,Bing Wei1,2Jie Ma,Jie Ma1,2Hongle Li,*Hongle Li1,2*Yongjun Guo,*Yongjun Guo1,2*
  • 1Department of Molecular Pathology, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, China
  • 2Henan Key Laboratory of Molecular Pathology, Zhengzhou, China
  • 3Department of Gynecologic Oncology, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, China
  • 4Department of Pathophysiology, School of Basic Medical Science, Zhengzhou University, Zhengzhou, China
  • 5Department of Pathology, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, China

A Corrigendum on:
Identification of BRCA1: c.5470_5477del as a Founder Mutation in Chinese Ovarian Cancer Patients

by Li J, Han S, Zhang C, Luo Y, Wang L, Wang P, Wang Y, Xia Q, Wang X, Wei B, Ma J, Li H and Guo Y (2021). Front. Oncol. 11:655709. doi: 10.3389/fonc.2021.655709

In the original article, we neglected to include the funder National Natural Science Foundation of China, 81802779 to Jun Li; Henan Provincial Health Commission, SBGJ202002020 to Jun Li; and Henan Science and Technology Project, 212102310675 to Jun Li.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s Note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: BRCA1/2, haplotype analysis, ovarian cancer, founder mutation, Chinese

Citation: Li J, Han S, Zhang C, Luo Y, Wang L, Wang P, Wang Y, Xia Q, Wang X, Wei B, Ma J, Li H and Guo Y (2022) Corrigendum: Identification of BRCA1:c.5470_5477del as a Founder Mutation in Chinese Ovarian Cancer Patients. Front. Oncol. 11:840551. doi: 10.3389/fonc.2021.840551

Received: 21 December 2021; Accepted: 22 December 2021;
Published: 14 January 2022.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2022 Li, Han, Zhang, Luo, Wang, Wang, Wang, Xia, Wang, Wei, Ma, Li and Guo. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Yongjun Guo, guoyongjun@zzu.edu.cn; Hongle Li, llhl73@163.com

†These authors have contributed equally to this work and share first authorship

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.